Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

$1.14 -0.01 (-0.44%)

High $1.17	Low $1.13	Trades 1,304	Turnover $2,983,889	Volume 2,606,681
30 June 2023 at 4:10pm

Market Cap (5-Oct) $2,649,039,360 (333rd)	Close (30-Jun) $1.14 0 (0%)	Volume (30-Jun) 2,606,681	Shortsold (29-Sep) 97,086,324 (7.48%) (33rd)
52w High $3.31	52w Low $1.88	P/E 454.55	EPS -0.06

Short Interest

ASIC data, 29 Sep 2026

% Shorted

7.48% 0.03

vs 7.51% prior report

Most Shorted Rank

33rd

of 693 shorted ASX stocks

Peak Short

11.00%

Oct 2015

Days to Cover

39.9

at 50d avg vol

View full short position history →

	Subject
	MSB MSB Article: Mesoblast needs capital raising, auditors say
	1 (current) 2 3
	MSB MSB Ann: Half Year Report and Accounts (including Appendix 4D)
	MSB MSB Ann: Trading Halt
	MSB MSB Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics
	MSB MSB Article: All of the profit results for today
	MSB MSB Article: Mesoblast ‘encouraged’ by back pain trial results
	MSB MSB Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
	MSB MSB Ann: Mesoblast Corporate Update Webcast
	MSB MSB Ann: Appendix 4C Quarterly Activity Report
	MSB MSB Ann: CHF Phase 3 Trial Results Presented at Investor Conference
	MSB MSB Ann: Mesoblast Healthcare Conference Investor Presentation
	MSB MSB Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
	MSB MSB Article: Mesoblast tipped to need $US75m cash injection
	MSB MSB Article: Mesoblast plunges on COVID-19 trial failure
	MSB MSB Ann: Mesoblast Webcast
	MSB MSB Ann: Mesoblast Update on COVID-19 ARDS Trial
	MSB MSB Ann: Trading halt
	MSB MSB Ann: Pause in Trading
	MSB MSB Article: Mesoblast shares smashed on Revascor trial
	MSB MSB Article: Mesoblast shares smashed on Revascor trial
	MSB MSB Ann: Mesoblast Phase 3 Chronic Heart Failure Results
	MSB MSB Ann: Mesoblast Corporate Update Webcast
	MSB MSB Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
	MSB MSB Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
	MSB MSB Ann: Appendix 2A
	MSB MSB Ann: Results of Meeting
	MSB MSB Ann: CEO Presentation to 2020 Annual General Meeting
	MSB MSB Ann: Mesoblast Chairman Message to 2020 AGM
	MSB MSB Ann: Novartis and Mesoblast Remestemcel-L Collaboration
	MSB MSB Ann: First Quarter Results Presentation
	MSB MSB Ann: MSB Q1 Financial Results and Operational Highlights
	MSB MSB Ann: First Quarter Financial Results on Form 6-K
	MSB MSB Ann: Mesoblast Corporate Update and Financial Results Webcast
	MSB MSB Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
	MSB MSB Ann: COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
	MSB MSB Ann: Annual Report to shareholders
	MSB MSB Ann: Notice of Annual General Meeting and Proxy Form
	MSB MSB Ann: Appendix 4G and Corporate Governance Statement
	MSB MSB Ann: Remestemcel Controlled Study in Crohns & Ulcerative Colitis

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

End of Day Prices

Date	Close	Volume	Change
05-Oct	$2.03	1,705,383	-0.01 (0.49%)
02-Oct	$2.04	2,015,258	-0.03 (1.45%)
01-Oct	$2.07	1,660,251	-0.04 (1.90%)
30-Sep	$2.11	2,171,589	0.00 (0.00%)
29-Sep	$2.11	1,911,161	+0.07 (3.43%)
28-Sep	$2.04	2,229,177	-0.12 (5.56%)
25-Sep	$2.16	1,402,530	-0.03 (1.37%)
24-Sep	$2.19	4,304,554	+0.01 (0.46%)
23-Sep	$2.18	1,760,354	+0.02 (0.93%)
22-Sep	$2.16	1,334,451	+0.03 (1.41%)
21-Sep	$2.13	1,859,655	+0.02 (0.95%)
18-Sep	$2.11	4,497,030	+0.05 (2.43%)
17-Sep	$2.06	2,825,991	+0.02 (0.98%)
16-Sep	$2.04	2,705,505	-0.02 (0.97%)
15-Sep	$2.06	2,006,395	-0.06 (2.83%)
7 up, 7 down, and 1 flat days

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Mesoblast Health Care Biopharmaceuticals Cancer Medicine Oncology

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology